Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
OABI 
OmniAb Inc. (OABI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: OABI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.33
1 Year Target Price $7.33
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 244.72M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 8 | Beta 0.85 | 52 Weeks Range 1.22 - 3.79 | Updated Date 02/21/2026 |
52 Weeks Range 1.22 - 3.79 | Updated Date 02/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -810.18% |
Management Effectiveness
Return on Assets (TTM) -12.69% | Return on Equity (TTM) -22.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 206293180 | Price to Sales(TTM) 11.6 |
Enterprise Value 206293180 | Price to Sales(TTM) 11.6 | ||
Enterprise Value to Revenue 9.85 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 143955400 | Shares Floating 96601271 |
Shares Outstanding 143955400 | Shares Floating 96601271 | ||
Percent Insiders 15.29 | Percent Institutions 52.35 |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb Inc. (NASDAQ: OABI) was founded in 2017, emerging from the strategic acquisition of Ligand Pharmaceuticals' OmniAb business. The company is a biotechnology firm focused on developing novel antibody-based therapeutics. It leverages its proprietary OmniAb platform to discover and develop fully human antibodies for a wide range of diseases. Key milestones include its spin-off from Ligand and subsequent IPO, aiming to accelerate its growth and expand its pipeline.
Core Business Areas
- Discovery and Development of Novel Antibodies: OmniAb Inc. utilizes its patented OmniAb platform to generate high-quality, fully human antibodies. This platform allows for rapid discovery and optimization of antibodies with desired therapeutic properties. The company's core business revolves around identifying and advancing these antibody candidates through preclinical and clinical development for various indications.
- Partnerships and Collaborations: A significant aspect of OmniAb's business model involves collaborating with other pharmaceutical and biotechnology companies. These partnerships typically involve licensing its antibody candidates or platform technology, generating revenue through upfront payments, milestones, and royalties.
Leadership and Structure
OmniAb Inc. is led by a management team with extensive experience in the biotechnology and pharmaceutical industries. The organizational structure is typical for a publicly traded biotech company, with dedicated departments for research and development, clinical operations, business development, and corporate functions. Specific leadership details can be found in their SEC filings.
Top Products and Market Share
Key Offerings
- OmniAb Platform: The core offering is the OmniAb platform, a proprietary antibody discovery technology that generates diverse, high-affinity, fully human antibodies. The platform is utilized both internally for pipeline development and externally through partnerships. Market share data for the platform itself is not directly quantifiable as it's a technology, but its success is reflected in the number and value of partnerships secured. Competitors in antibody discovery platforms include technologies offered by companies like Adimab, AbCellera, and Regeneron Pharmaceuticals (VelociGene).
- Internal Pipeline Candidates: OmniAb has a pipeline of antibody candidates targeting various diseases, including autoimmune disorders, cancer, and infectious diseases. Specific product names and their developmental stages are detailed in company reports. Revenue generated from these candidates comes from potential future approvals and royalties from partnered programs. Competitors vary greatly depending on the specific therapeutic area and target.
Market Dynamics
Industry Overview
OmniAb operates within the rapidly growing biotechnology and biopharmaceutical industry, specifically focusing on antibody-based therapeutics. This sector is characterized by high R&D investment, significant scientific innovation, and a strong demand for novel treatments for unmet medical needs. The market is competitive, with numerous companies pursuing similar therapeutic targets.
Positioning
OmniAb is positioned as a leader in fully human antibody discovery through its proprietary OmniAb platform. Its competitive advantage lies in the speed, diversity, and quality of antibodies generated by its platform, enabling rapid advancement of drug candidates and attractive partnership opportunities. The company's strategy focuses on leveraging this platform to build a robust pipeline and forge strategic alliances.
Total Addressable Market (TAM)
The TAM for antibody-based therapeutics is substantial and continues to grow, driven by advancements in understanding disease mechanisms and the development of highly targeted treatments. While a precise TAM for OmniAb's specific antibody discovery niche is difficult to quantify, the broader market for monoclonal antibodies alone is in the tens of billions of dollars globally. OmniAb is positioned to capture a portion of this market by providing innovative antibody discovery solutions to its partners and advancing its own internal pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary OmniAb antibody discovery platform with proven efficacy.
- Strong potential for high-affinity, fully human antibodies.
- Established partnerships and revenue streams from collaborations.
- Experienced management team with a track record in biotech.
- Focus on a key therapeutic modality (antibodies) with broad application.
Weaknesses
- Reliance on external partnerships for significant revenue.
- Long development timelines and high costs associated with drug development.
- Potential for clinical trial failures.
- Limited commercialization experience for its own products.
- Competition from established pharmaceutical companies and other antibody discovery platforms.
Opportunities
- Expansion into new therapeutic areas and indications.
- Deepening existing partnerships and securing new strategic alliances.
- Advancing its internal pipeline to late-stage clinical trials and potential commercialization.
- Leveraging advancements in AI and machine learning for drug discovery.
- Potential for growth through acquisitions or mergers.
Threats
- Intense competition in the biopharmaceutical market.
- Regulatory hurdles and changes in healthcare policies.
- Patent expirations and generic competition for approved drugs.
- Economic downturns impacting R&D spending and investment.
- Emergence of disruptive technologies in drug discovery.
Competitors and Market Share
Key Competitors
- Adimab (Private)
- AbCellera Biologics Inc. (Private)
- Regeneron Pharmaceuticals, Inc. (REGN)
- Merck & Co., Inc. (MRK)
Competitive Landscape
OmniAb's competitive advantages lie in its specialized OmniAb platform and its focus on fully human antibodies, offering potentially lower immunogenicity. However, it faces intense competition from larger pharmaceutical companies with extensive R&D resources and established commercial infrastructure, as well as other specialized antibody discovery companies. Key differentiators often come down to platform efficiency, speed of discovery, and the quality/novelty of the generated antibodies.
Growth Trajectory and Initiatives
Historical Growth: OmniAb's historical growth has been characterized by the evolution of its OmniAb platform and the establishment of key partnerships. Following its spin-off and IPO, growth has been focused on expanding its R&D capabilities and securing collaborations to monetize its technology and pipeline.
Future Projections: Future projections for OmniAb Inc. are dependent on the successful progression of its internal pipeline, the continued success of its partnered programs, and the ability to secure new, significant collaborations. Analyst estimates will typically focus on potential revenue growth from milestone payments, royalties, and the ultimate commercialization of its drug candidates.
Recent Initiatives: Recent initiatives likely include the expansion of its research programs into new therapeutic areas, strengthening its scientific advisory board, pursuing new partnership opportunities, and potentially advancing its lead internal candidates into later stages of clinical development. Strategic investments in platform enhancements are also probable.
Summary
OmniAb Inc. is a promising biotechnology company with a strong antibody discovery platform. Its core strength lies in generating novel, fully human antibodies, which has led to valuable partnerships. However, the company faces typical biotech challenges, including a long development cycle, high R&D costs, and significant competition. Its future success hinges on the continued validation of its platform, the progression of its pipeline, and the ability to secure and manage strategic collaborations effectively.
Similar Stocks
Sources and Disclaimers
Data Sources:
- OmniAb Inc. SEC Filings (10-K, 10-Q, S-1)
- Company Investor Relations Websites
- Biotechnology Industry Reports
- Financial Data Providers (e.g., Bloomberg, Refinitiv - data simulated for this analysis)
Disclaimers:
This JSON output is an analysis based on publicly available information and general industry knowledge. It is not financial advice. All numerical data and market share figures are illustrative and may not reflect real-time or precise market conditions. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2022-11-02 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.